Trials / Conditions / EGFR Mutant Advanced Non-small Cell Lung Cancer
EGFR Mutant Advanced Non-small Cell Lung Cancer
5 registered clinical trials studyying EGFR Mutant Advanced Non-small Cell Lung Cancer — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor NCT07143045 | Alpha Biopharma (Jiangsu) Co., Ltd. | — |
| Terminated | A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients NCT06186076 | Therapex Co., Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment NCT05920135 | Bridge Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NCT05394831 | J Ints Bio | Phase 1 / Phase 2 |
| Unknown | Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor ( NCT03994393 | University of Sydney | Phase 2 |